Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

Tesamorelin

FDA Approved

Growth Hormone · Theratechnologies

Growth hormone-releasing factor (GRF) analog approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also used off-label as a growth hormone secretagogue.

About

Mechanism

Synthetic analog of human growth hormone-releasing factor (GRF 1-44). Binds to GRF receptors in the pituitary to stimulate endogenous growth hormone synthesis and release, preserving the pulsatile secretion pattern.

Half-Life

Approximately 26 minutes (terminal half-life of the peptide itself; GH effects last longer)

Route

subcutaneous

Frequency

Once daily

Clinical Dosing

2 mgonce daily

FDA-approved for HIV-associated lipodystrophy. Off-label use for GH optimization is not covered by the FDA indication.

Titration Protocols

Egrifta SV Label Dosing

Source: Egrifta SV (tesamorelin) prescribing information, Theratechnologies, 2019

Dose	Duration	Draw (2 mg vial in 2mL)	Notes
2 mg	Maintenance	2.00 mL (200 units)	Fixed daily dose, no titration required

Available Vial Sizes

2 mg

2 mg vial

Citations

[1]Egrifta SV (tesamorelin for injection) - Prescribing Information. FDA / Theratechnologies. Link(Reviewed: 2024-01-01)
[2]Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients (LIPO-010). Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. Link(Reviewed: 2024-01-01)